Why can safety concerns make it difficult to standardize drug approval rules internationally?

Standardizing drug approval rules internationally is challenging primarily because every new drug is unique, which can lead to unforeseen safety or efficacy issues during the regulatory review process. While international bodies like the World Health Organization promote harmonization to simplify global marketing, individual regulatory agencies maintain the authority to demand additional, specific studies if they identify potential risks.1

Because the use of any medication carries an inherent risk of adverse events, governments have a fundamental moral obligation to prioritize public health by ensuring that the risk-to-benefit ratio of any drug is favorable. When unexpected safety concerns arise, a national agency may prioritize local safety standards over international uniformity to prevent harm from toxic impurities, unrecognized adverse reactions, or adulterated products. Consequently, while harmonization aims to reduce development costs, the necessity of rigorous, independent oversight to protect the common good often makes achieving universal regulatory agreement complex and difficult.213